Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
881-900 of 1,743 trials

Childhood Cancer: Vaccine Response Study for Measles and Chickenpox

We are examining how well children and teens with a history of childhood cancer respond to vaccines for measles and chickenpox after treatment. This study aims to understand their immunity levels and how treatment affects their ability to fight these diseases.

Pediatric Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesOncologyPediatrics

AMG 193 for Advanced Gastrointestinal and Pancreatic Cancers

We are testing AMG 193 combined with other therapies for patients with advanced gastrointestinal, biliary tract, or pancreatic cancers that have a specific genetic deletion. The goal is to see if this combination improves treatment outcomes.

Biliary and Pancreatic Cancer>2 yearsSafety phase (I)Oncology

Non-Small Cell Lung Cancer: U3-1402 Treatment

We are studying a new treatment called U3-1402 for individuals with non-small cell lung cancer. The goal is to see how well it works compared to current therapies.

Metastatic Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Breast Cancer: Abemaciclib with Endocrine Therapy

We are studying a combination of Abemaciclib and endocrine therapy for patients with advanced hormone receptor positive HER2 negative breast cancer. The trial focuses on how well this treatment works and how we can manage side effects using digital tools.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsMonitoring phase (IV)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Carpal Tunnel Syndrome: Injection vs. Surgery

We are comparing the effectiveness of ultrasound-guided injections to surgery for treating carpal tunnel syndrome. This study will help determine which approach may be better for patients in the long run.

Carpal Tunnel Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

THEO-260 for Ovarian Cancer Treatment

We are studying a new treatment for patients with high-grade serous or endometrioid ovarian cancer to see if it is safe and effective. This trial will help us understand the best dose and how well it works compared to existing options.

Ovarian Cancer>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Advanced Solid Tumors: LY4170156 Treatment

We are studying a new treatment called LY4170156 for people with advanced solid tumors. The goal is to understand its safety and how well it works compared to current options.

Solid Tumors>2 yearsSafety phase (I)Oncology

Non-Small Cell Lung Cancer: Alectinib and Chemotherapy Study

We are investigating how well alectinib combined with chemotherapy works for patients with early-stage non-small cell lung cancer. This study focuses on those whose cancer can be surgically removed and who have specific biomarker characteristics.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Atopic Dermatitis: APG777 Treatment Study

We are studying a new treatment called APG777 for people with moderate-to-severe atopic dermatitis. The goal is to see if it helps reduce symptoms like itching and skin pain compared to a placebo.

Atopic Dermatitis>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Glioblastoma: Meclofenamate with Temozolomide

We are studying whether adding meclofenamate to standard temozolomide therapy helps patients with progressive MGMT-methylated glioblastoma. The trial will assess safety, effectiveness, and quality of life improvements.

Glioblastoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Colorectal Polyp Removal: Anticoagulants and Antiplatelets Study

We are investigating whether continuing blood-thinning medications during polypectomy for small colorectal polyps affects bleeding risks. This study will also assess heart-related risks when these medications are stopped.

Healthy Participants Undergoing Colonoscopy>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyHematology

Blood Cancer: Long-term Study of Zanubrutinib

We are evaluating the long-term safety and effectiveness of Zanubrutinib in patients with B-cell malignancies. This study is for those who have previously participated in a related trial.

B-cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Non-Small Cell Lung Cancer: Sotorasib Treatment Study

We are studying the effects of Sotorasib in patients with non-operable non-small cell lung cancer who have a KRAS mutation. The goal is to see if this treatment improves survival and response rates compared to standard options.

Stage III Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Amyotrophic Lateral Sclerosis: ARGX-119 Study

We are testing a new treatment called ARGX-119 for adults with ALS to see if it is safe and how well it works in slowing disease progression.

Amyotrophic Lateral Sclerosis (ALS)>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Acute Pulmonary Embolism: Reduced Dose Thrombolytic Treatment

We are studying whether a lower dose of thrombolytic therapy is effective and safe for patients with intermediate high-risk acute pulmonary embolism. This research aims to improve treatment outcomes and reduce health risks.

Pulmonary Embolism>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCardiologyInternal MedicinePulmonology

Tafasitamab for Pediatric Acute B Lineage Leukemia

We are studying a new treatment for children with relapsed or refractory acute B lineage leukemia to see if it can help delay disease relapse and improve survival rates.

Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyPediatrics

Oral Propranolol for Preventing Eye Issues in Premature Infants

We are studying whether oral propranolol can help extremely preterm infants lower their risk of developing threshold retinopathy of prematurity. This research aims to improve safety and reduce the need for additional treatments.

Retinopathy of Prematurity>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteOphthalmologyPediatrics

Acute Myeloid Leukemia: New Oral Drug for IDH1 Mutation

We are testing a new oral medication for patients with AML or other blood cancers that have an IDH1 mutation. The study aims to evaluate the safety and activity of this investigational drug.

Acute Myeloid Leukaemia>2 yearsSafety phase (I)HematologyOncology

Cobolimab and Dostarlimab for Pediatric Tumors

We are studying a combination of two medications for children and young adults with newly diagnosed or relapsed solid tumors. The goal is to evaluate safety and how well it may work against specific cancers.

Hepatic CancerRhabdomyosarcomaGlioma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyPediatrics

Sasanlimab for Muscle Invasive Bladder Cancer

We are studying whether sasanlimab can help patients with muscle invasive bladder cancer keep their bladder intact after initial treatment. The trial looks at survival rates and quality of life for participants.

Invasive Bladder Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology